Norway
· Delayed Price · Currency is NOK Lytix Biopharma AS Company Description
Lytix Biopharma AS, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States.
Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, which is in Phase II clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma.
The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as hepatocellular carcinoma in liver cancer and liver metastases.
It has a partnership with Verrica Pharmaceuticals Inc. for the development and commercialization of LTX-315 for the treatment of all malignant and pre-malignant dermatological indications.
Lytix Biopharma AS was founded in 2003 and is based in Oslo, Norway.
| Country | Norway |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Oystein Rekdal |
Contact Details
Address: Sandakerveien 138 Oslo, 0484 Norway | |
| Website | lytixbiopharma.com |
Stock Details
| Ticker Symbol | LYTIX |
| Exchange | Oslo Børs |
| Fiscal Year | January - December |
| Reporting Currency | NOK |
| ISIN Number | NO0010405780 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Oystein Rekdal Ph.D. | Co-Founder and Chief Executive Officer |
| Gjest Breistein M.Sc. | Chief Financial Officer |
| Dr. Baldur Sveinbjørnsson Ph.D. | Chief Scientific Officer |
| Dr. Mette Husbyn Ph.D. | Chief Technology Officer |
| Ole Peter Nordby | Head of IR and Communication Manager |
| Jacqueline Earabino | Head of Clinical Operations |